Page last updated: 2024-09-05

beta-solamarine and u 0126

beta-solamarine has been researched along with u 0126 in 1 studies

Compound Research Comparison

Studies
(beta-solamarine)
Trials
(beta-solamarine)
Recent Studies (post-2010)
(beta-solamarine)
Studies
(u 0126)
Trials
(u 0126)
Recent Studies (post-2010) (u 0126)
632382,81621,213

Protein Interaction Comparison

ProteinTaxonomybeta-solamarine (IC50)u 0126 (IC50)
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.29
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.25
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)0.07
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)0.2816
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)0.2529

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ao, S; Dong, B; Du, H; Fu, R; Hu, Y; Ji, J; Lv, G; Sun, Z; Wang, X; Zhang, L1

Other Studies

1 other study(ies) available for beta-solamarine and u 0126

ArticleYear
Solamargine inhibits gastric cancer progression by regulating the expression of lncNEAT1_2 via the MAPK signaling pathway.
    International journal of oncology, 2019, Volume: 54, Issue:5

    Topics: Animals; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Nitriles; RNA, Long Noncoding; Solanaceous Alkaloids; Stomach Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays

2019